Anti-ENO1 antibody combined with metformin against tumor resistance: a novel antibody-based platform.

ABSTRACT:

Background

Antibody-based platforms (i.e., ADC) have emerged as one of the most encouraging tools for the cancer resistance caused by cancer stem cells (CSCs) enrichment. Our study might provide a promising therapeutic direction against drug resistance and serve as a potential precursor platform for screening ADC.

Methods

The cell migration, invasion, drug resistance, and self-renewal were assessed by the cell invasion and migration assay, wound healing assay, CCK-8 assay, colony formation assay, and sphere formation assay, respectively. The expression profiles of CSCs (ALDH⁺ and CD44⁺) subpopulations were screened by flow cytometry. The western blot and cell immunofluorescence assay were used to evaluate pathway-related protein expression in bot

SUBMITTER: Shu X 

PROVIDER: S-EPMC10956521 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature